RGNX | REGENXBIO Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	11.16 - 11.64
52 Week Range	10.49 - 28.80
Beta	1.20
Implied Volatility	277.55%
IV Rank	96.46%
Day's Volume	356,132
Average Volume	577,659
Shares Outstanding	49,423,200
Market Cap	567,378,336
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-09-17

Valuation
Profitability
Growth
Health
P/E Ratio	-2.19
Forward P/E Ratio	-6.85
EPS	-5.24
1YR Price Target	57.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	344
Country	USA
Website	RGNX

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

RGNX's peers: ABEO, ACIU, CLLS, CRNX, KRYS, QURE, RCKT, DAWN, REPL, MIRM, RNA, PTGX, PLRX, IMCR, RVMD, GLUE, STOK, ANTX, PASG, FDMT, LIAN, KZR, SYRS, VCEL, IVVD

*Chart delayed

Analyzing fundamentals for RGNX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is very weak. For more detailed analysis please see RGNX Fundamentals page.

Watching at RGNX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RGNX Technicals page.